Asia-Pacific breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 10.1% during the forecast period. Increasing the incidence of breast cancer coupled with a growing awareness program towrds breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. Breast cancer has emerged as a major health issue in the country. Australia is estimated to have the highest rate of breast cancer incidences in the Asia-Pacific. The incidence rate of breast cancer in Australia was estimated to be around 86 per 100,000 women in 2015 as per Cancer Australia and further projected to increase in the future. Obesity, alcohol consumption and smoking are some of the major factors that are backing the increasing prevalence of breast cancer in Australia. Further, Singapore, Taiwan, and Hong Kong also estimated to have a high incidence rate of breast cancer with 65.7, 65.9 and 61.2 per 100,000 women respectively as per WHO.
Asia-Pacific breast cancer diagnostics and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
To Request a Sample of our Report on Asia-Pacific Breast Cancer Diagnostics And Therapeutics Market: https://www.omrglobal.com/request-sample/asia-pacific-breast-cancer-diagnostics-therapeutics-market
Asia-Pacific Breast Cancer Diagnostics And Therapeutics Market Segmentation
By Cancer Type
- Ductal Carcinoma In-Situ (DCIS)
- Invasive Ductal Carcinoma (IDC)
- Triple Negative Breast Cancer (TNBC)
- Inflammatory Breast Cancer
- Others (Invasive lobular carcinoma)
By Diagnostics
- Mammography
- Biopsy
- PET/CET
- Ultrasound
- Others (MRI)
By Therapeutics
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Others (Radiation Therapy, Surgery)
A full Report of Asia-Pacific Breast Cancer Diagnostics And Therapeutics Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-breast-cancer-diagnostics-therapeutics-market
Regional Analysis
- China
- India
- Japan
Rest of Asia-Pacific
Company Profiles
- AstraZeneca PLC
- Bayer AG
- GlaxoSmithKline PLC
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Hoffmann-La Roche AG
- Sanofi S.A.
- Siemens Healthcare GmbH
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
